Dr. Aishwarya N., MBBS

Active Clinical Contributor & Author

Clinical Articles & Analysis by Dr. Aishwarya N., MBBS

644 Articles

Hydrochlorothiazide label details renal risk, electrolyte monitoring, and glaucoma warning

DailyMed labeling for hydrochlorothiazide reviews renal and electrolyte risks, drug interactions, pregnancy cautions, and rare acute angle-closure glaucoma.

Nov 4, 2026

Cardiology·ScienceDaily

Gene Editing for Heart Disease Raises Safety and Access Questions

A JAMA Internal Medicine perspective weighs gene editing for cholesterol and heart disease against irreversible risk, long-term monitoring,…

Nov 4, 2026

Cardiology·Nature

EASIX Predicts Delirium and Mortality After Valve Surgery

Early postoperative EASIX predicted delirium and in-hospital death after cardiac valve replacement in a MIMIC-IV cohort of 1,543…

Nov 4, 2026

Vascular Medicine·BBC Dental

Peripheral Arterial Disease Warning Signs Can Prevent Amputation

A Leicester campaign urges earlier recognition of peripheral arterial disease symptoms after cases of limb loss and delayed…

Nov 4, 2026

Cardiology·JAMA Onc

Cardiovascular Trial Representation Demands Design-Level Reform

A JAMA Cardiology review outlines policies and trial-design strategies needed to improve representation, validity, and equity in cardiovascular…

Nov 4, 2026

Cardiology·Modern HC

TAVR Cost Pressures Force Hospitals to Rethink Program Economics

Hospitals running TAVR programs face steep costs and tight margins, making efficiency, volume, and care coordination central to…

Nov 4, 2026

Cardiology·JACC

SINGLE-CLOSURE Trial tests one vs two ProGlide devices after TAVR

The SINGLE-CLOSURE Trial examines whether one ProGlide device can secure transfemoral TAVR access as effectively as two devices.

Nov 4, 2026

Cardiology·JACC

Japan LVAD Risk Stratification Tool Draws JACC: Asia Podcast Review

JACC: Asia reviews a mandated risk stratification tool for destination therapy LVAD in Japan, but the RSS abstract…

Nov 4, 2026

Cardiology·JACC

Osteosarcopenia Linked to Atrial Fibrillation Risk in Multi-Cohort Study

A JACC: Asia podcast episode examines whether osteosarcopenia, the combined loss of bone and muscle, marks higher atrial…

Nov 4, 2026

Cardiology·ACC-PRO

Pfizer ends phase 2 PAH program targeting BMP9 on business grounds

Pfizer has stopped its phase 2 PF-07868489 pulmonary arterial hypertension program, ending a BMP9 strategy despite earlier biologic…

Nov 4, 2026

Independent Review Board

All articles authored by our clinical fellows are cross-audited by MWF Review Team featuring 10 senior department chairs from premier hospitals.

Explore Review Team

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.